Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials
Maria M. Simile, Paola Bagella, Gianpaolo Vidili, et al.
Medicina (2019) Vol. 55, Iss. 2, pp. 42-42
Open Access | Times Cited: 72

Showing 26-50 of 72 citing articles:

Effects of Oncolytic Vaccinia Viruses Harboring Different Marine Lectins on Hepatocellular Carcinoma Cells
Yanrong Zhou, Qianpeng Wang, Qi Ying, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3823-3823
Open Access | Times Cited: 8
Precision Medicine in Cholangiocarcinoma: Past, Present, and Future
Chi-Yuan Cheng, Chiao‐Ping Chen, Chiao‐En Wu
Life (2022) Vol. 12, Iss. 6, pp. 829-829
Open Access | Times Cited: 12
Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation
Kyaw Zwar Myint, Brinda Balasubramanian, Simran Venkatraman, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 197-197
Open Access | Times Cited: 2
Ex vivo liver resection and auto-transplantation and special systemic therapy in perihilar cholangiocarcinoma treatment
Konstantin Y Tchilikidi
World Journal of Gastrointestinal Surgery (2024) Vol. 16, Iss. 3, pp. 635-640
Open Access | Times Cited: 2
Venous thromboembolism in patients undergoing distal cholangiocarcinoma surgery: Prevalence, risk factors, and outcomes
Qing Chen, Songping Cui, Jincan Huang, et al.
Asian Journal of Surgery (2023) Vol. 46, Iss. 9, pp. 3648-3655
Open Access | Times Cited: 6
Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma
Natalie Bath, Timothy M. Pawlik
Chinese Clinical Oncology (2023) Vol. 12, Iss. 1, pp. 5-5
Open Access | Times Cited: 6
Cholangiocarcinoma: investigations into pathway-targeted therapies
Ioannis Ntanasis‐Stathopoulos, Diamantis I. Tsilimigras, Maria Gavriatopoulou, et al.
Expert Review of Anticancer Therapy (2020) Vol. 20, Iss. 9, pp. 765-773
Closed Access | Times Cited: 16
NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials
Zainul Abedin Kapacee, Jennifer J. Knox, Daniel H. Palmer, et al.
Medical Oncology (2020) Vol. 37, Iss. 7
Closed Access | Times Cited: 15
Different interventional time of hepatic arterial infusion with PD-1 inhibitor for advanced biliary tract cancer: a multicenter retrospective study.
Ting Zhang, Xu Yang, Xiaobo Yang, et al.
PubMed (2022) Vol. 12, Iss. 7, pp. 3455-3463
Closed Access | Times Cited: 10
Current Endoscopic Management of Malignant Biliary Stricture
Chi‐Chih Wang, Tzu‐Wei Yang, Wen‐Wei Sung, et al.
Medicina (2020) Vol. 56, Iss. 3, pp. 114-114
Open Access | Times Cited: 13
GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration
Jun Zhou, Wanpin Nie, Jiajia Yuan, et al.
Oncology Reports (2021) Vol. 45, Iss. 6
Open Access | Times Cited: 12
Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy
Evangelos Koustas, Eleni-Myrto Trifylli, Panagiotis Sarantis, et al.
World Journal of Gastrointestinal Oncology (2021) Vol. 13, Iss. 10, pp. 1229-1243
Open Access | Times Cited: 12
Licochalcone A Induces Cholangiocarcinoma Cell Death Via Suppression of Nrf2 and NF-κB Signaling Pathways
Phatthamon Laphanuwat, Sarinya Kongpetch, Laddawan Senggunprai, et al.
Asian Pacific Journal of Cancer Prevention (2022) Vol. 23, Iss. 1, pp. 115-123
Open Access | Times Cited: 9
Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study
Ge Zhang, Shuai Gong, Lina Pang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 11
Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy.
Panagiotis Sarantis, Eleftheria Dikoglou Tzanetatou, Evangelia Ioakeimidou, et al.
PubMed (2021) Vol. 13, Iss. 12, pp. 13246-13260
Closed Access | Times Cited: 11
Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma
Antonio Cigliano, Maria G. Pilo, Marta Mela, et al.
Medicina (2019) Vol. 56, Iss. 1, pp. 1-1
Open Access | Times Cited: 12
Proteomic analyses reveal divergent ubiquitylation patterns in hepatocellula carcinoma cell lines with different metastasis potential
Ying Sun, Xiaoyuan Zheng, Hui Yuan, et al.
Journal of Proteomics (2020) Vol. 225, pp. 103834-103834
Closed Access | Times Cited: 11
Current Advances in Basic and Translational Research of Cholangiocarcinoma
Keisaku Sato, Leonardo Baiocchi, Lindsey Kennedy, et al.
Cancers (2021) Vol. 13, Iss. 13, pp. 3307-3307
Open Access | Times Cited: 10
pH and Redox-Dual Sensitive Chitosan Nanoparticles Having Methyl Ester and Disulfide Linkages for Drug Targeting against Cholangiocarcinoma Cells
Ju-Il Yang, Hye Lim Lee, Je-Jung Yun, et al.
Materials (2022) Vol. 15, Iss. 11, pp. 3795-3795
Open Access | Times Cited: 7
Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma
Philipp Heumann, Andreas Albert, Karsten Gülow, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1690-1690
Open Access | Times Cited: 1
Practical considerations for pathological diagnosis and molecular profiling of cholangiocarcinoma: an expert review for best practices
Matthew Evans, Timothy J. Kendall
Expert Review of Molecular Diagnostics (2024) Vol. 24, Iss. 5, pp. 393-408
Closed Access | Times Cited: 1
KRAS and BRAF genetic alterations in lung cancer: A case − control study
Humaira Aziz Sawal, Syeda Ibtesam Shah, Saima Shakil Malik, et al.
Journal of Cancer Research and Therapeutics (2024) Vol. 20, Iss. 3, pp. 782-787
Open Access | Times Cited: 1
Current omics-based biomarkers for cholangiocarcinoma
Kitti Intuyod, Napat Armartmuntree, Apinya Jusakul, et al.
Expert Review of Molecular Diagnostics (2019) Vol. 19, Iss. 11, pp. 997-1005
Closed Access | Times Cited: 10
Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma
Brinda Balasubramanian, Simran Venkatraman, Kyaw Zwar Myint, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 1, pp. 51-51
Open Access | Times Cited: 8
Patterns of Whole Exome Sequencing in Resected Cholangiocarcinoma
Lucas W. Thornblade, Paul Wong, Daneng Li, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 4062-4062
Open Access | Times Cited: 8

Scroll to top